Article

G protein betagamma subunits as targets for small molecule therapeutic development.

Department of Pharmacology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Combinatorial chemistry & high throughput screening (Impact Factor: 2.46). 07/2008; 11(5):382-95.
Source: PubMed

ABSTRACT G proteins mediate the action of G protein coupled receptors (GPCRs), a major target of current pharmaceuticals and a major target of interest in future drug development. Most pharmaceutical interest has been in the development of selective GPCR agonists and antagonists that activate or inhibit specific GPCRs. Some recent thinking has focused on the idea that some pathologies are the result of the actions of an array of GPCRs suggesting that targeting single receptors may have limited efficacy. Thus, targeting pathways common to multiple GPCRs that control critical pathways involved in disease has potential therapeutic relevance. G protein betagamma subunits released from some GPCRs upon receptor activation regulate a variety of downstream pathways to control various aspects of mammalian physiology. There is evidence from cell- based and animal models that excess Gbetagamma signaling can be detrimental and blocking Gbetagamma signaling has salutary effects in a number of pathological models. Gbetagamma regulates downstream pathways through modulation of enzymes that produce cellular second messengers or through regulation of ion channels by direct protein-protein interactions. Thus, blocking Gbetagamma functions requires development of small molecule agents that disrupt Gbetagamma protein interactions with downstream partners. Here we discuss evidence that small molecule targeting Gbetagamma could be of therapeutic value. The concept of disruption of protein-protein interactions by targeting a "hot spot" on Gbetagamma is delineated and the biochemical and virtual screening strategies for identification of small molecules that selectively target Gbetagamma functions are outlined. Evaluation of the effectiveness of virtual screening indicates that computational screening enhanced identification of true Gbetagamma binding molecules. However, further refinement of the approach could significantly improve the yield of Gbetagamma binding molecules from this screen that could result in multiple candidate leads for future drug development.

1 Bookmark
 · 
87 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The rationale for identifying drug targets within helminth neuromuscular signalling systems is based on the premise that adequate nerve and muscle function is essential for many of the key behavioural determinants of helminth parasitism, including sensory perception/host location, invasion, locomotion/orientation, attachment, feeding and reproduction. This premise is validated by the tendency of current anthelmintics to act on classical neurotransmitter-gated ion channels present on helminth nerve and/or muscle, yielding therapeutic endpoints associated with paralysis and/or death. Supplementary to classical neurotransmitters, helminth nervous systems are peptide-rich and encompass associated biosynthetic and signal transduction components – putative drug targets that remain to be exploited by anthelmintic chemotherapy. At this time, no neuropeptide system-targeting lead compounds have been reported, and given that our basic knowledge of neuropeptide biology in parasitic helminths remains inadequate, the short-term prospects for such drugs remain poor. Here, we review current knowledge of neuropeptide signalling in Nematoda and Platyhelminthes, and highlight a suite of 19 protein families that yield deleterious phenotypes in helminth reverse genetics screens. We suggest that orthologues of some of these peptidergic signalling components represent appealing therapeutic targets in parasitic helminths.
    International journal for parasitology 01/2012; 2:76–91. · 3.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The function of Kruppel-like Factor 11 (KLF11) in the regulation of metabolic pathways is conserved from flies to human. Alterations in KLF11 function result in Maturity Onset Diabetes of the Young 7 (MODY7) and neonatal diabetes, however, the mechanisms underlying the role of this protein in metabolic disorders remain unclear. Here, we seek to investigate how the A347S genetic variant, present in MODY7 patients, modulates KLF11 transcriptional activity. A347S affects a previously identified transcriptional regulatory domain 3 (TRD3) for which co-regulators remain unknown. Structure-oriented sequence analyses, described here, predict that the KLF11 TRD3 represents an evolutionarily conserved protein domain. Combined, yeast two-hybrid and protein arrays demonstrate that the TRD3 binds WD40, WWI, WWII, and SH3-domain containing proteins. Using one of these proteins as a model, guanine nucleotide binding protein beta 2 (Gβ2), we investigate the functional consequences of KLF11 coupling to a TRD3 binding partner. Combined, immunoprecipitation and biomolecular fluorescence complementation assays confirm that activation of three different metabolic GPCR receptors (β-adrenergic, secretin and CCK) induce nuclear translocation of Gβ2 to directly bind KLF11 in a manner that is disrupted by the MODY7 A347S variant. Using genome-wide expression profiles, we identify metabolic gene networks impacted upon TRD3 disruption. Furthermore, A347S disrupts KLF11-mediated increases in basal insulin levels and promoter activity, combined with blunted glucose-stimulated insulin secretion. Thus, this study characterizes a novel protein-protein interaction domain disrupted in a KLF gene variant that associates to MODY7, contributing to our understanding of gene regulation events in complex metabolic diseases.
    Journal of Biological Chemistry 04/2013; · 4.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: G-Protein-coupled receptors (GPCRs) signal through G protein α and βγ subunit families to regulate a wide range of physiological and pathophysiological processes. As such, GPCRs are major targets for therapeutic drugs. Downstream targets of GPCRs have also gained interest as a therapeutic approach to complex pathologies involving multiple GPCRs. One such approach involves targeting of the G proteins themselves. Several small molecule Gα and Gβγ modulators have been developed and been tested in various animal models of disease. Here we will discuss the requirements for targeting Gα and Gβγ subunits, the mechanisms of action of currently identified inhibitors, and focus on the potential utility of Gα and Gβγ inhibitors in the treatment of various cancers.
    Trends in Pharmacological Sciences 04/2013; · 9.25 Impact Factor

Full-text

Download
1 Download
Available from